Sulforaphane for Chronic Kidney Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether sulforaphane, a compound found in broccoli, can slow the progression of Chronic Kidney Disease (CKD) and reduce inflammation and oxidative stress, harmful processes in the body. Participants will take either a sulforaphane supplement or a placebo (a pill with no active ingredient) to compare effects. This trial may suit those with CKD who have noticed declining kidney function over the past year. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on anticoagulants (blood thinners) or immunosuppression (medications that lower the immune system).
Is there any evidence suggesting that Sulforaphane (Avmacol Extra Strength) is likely to be safe for humans?
Research has shown that sulforaphane, an ingredient in Avmacol Extra Strength, is safe for use. In studies involving individuals with Chronic Kidney Disease (CKD), taking four tablets daily was well-tolerated, with no serious side effects reported. Some research indicates that sulforaphane reaches its peak level in the blood of CKD patients more slowly than in those without CKD, but this does not appear to impact its safety.
Overall, evidence suggests that Avmacol Extra Strength is safe, with no major negative effects reported.12345Why do researchers think this study treatment might be promising for chronic kidney disease?
Researchers are excited about sulforaphane (Avmacol Extra Strength) for chronic kidney disease because it offers a fresh approach with its active ingredient derived from broccoli sprouts. Unlike the standard treatments, which often focus on controlling blood pressure and blood sugar, sulforaphane works by potentially reducing inflammation and oxidative stress in the kidneys. This unique mechanism could provide a new avenue for protecting kidney function, which is why it's generating interest in the medical community.
What evidence suggests that Sulforaphane might be an effective treatment for Chronic Kidney Disease?
Research has shown that sulforaphane, an ingredient in Avmacol Extra Strength, might help slow chronic kidney disease (CKD). Studies have found that it can reduce signs of cell damage and inflammation, which are often elevated in people with CKD. This trial will test sulforaphane as a treatment option, with participants taking four tablets of Avmacol Extra Strength daily. This suggests that sulforaphane could help manage CKD by protecting the kidneys from further harm. While these findings are promising, additional trials are needed to confirm its benefits for CKD patients.12346
Are You a Good Fit for This Trial?
Adults aged 18-80 with moderate chronic kidney disease, specifically those whose kidneys are filtering at a reduced rate and have shown decline in the past year. Participants must be able to swallow pills and give consent. Excluded are pregnant or breastfeeding individuals, those on anticoagulants or immunosuppressants, cancer patients, non-English speakers, and anyone with severe health issues affecting survival beyond a year.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pharmacokinetic (PK) Phase
Establishing a safe dose of 4 tablets once daily in participants with CKD Stages 3 - 4
Treatment
Participants receive either Avmacol ES or placebo in a randomized, double-blind manner
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Sulforaphane (Avmacol Extra Strength)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
Nutramax Laboratories, Inc.
Industry Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
University of Virginia
Collaborator